Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 


Genesis Research and EvoGenix To Collaborate


Genesis Research and EvoGenix To Collaborate On Discovery Of Novel Anti-Inflammatory Agents

Genesis Research and Development Corporation Limited (NZSE/ASX: GEN) and EvoGenix Pty Limited today announced the signing of a collaboration agreement to undertake a joint research and development program to discover novel anti-inflammatory drugs.

Through its genomics research to identify potential drug targets, Genesis has discovered a novel immune modulator which may be a key regulator in some inflammatory conditions. EvoGenix will apply its expertise in the discovery and optimisation of protein therapeutics in collaboration with Genesis to evaluate this molecule as a drug target.

In Phase I of the research project Genesis and EvoGenix will screen and test sequences in a library of antibody-like molecules to identify inhibitors of specific biological activity. Later phases of the work will involve selection of an appropriate therapeutic molecule to focus on targets in inflammation and undertake extensive laboratory testing before commencing patient trials.

CEO of EvoGenix Dr Merilyn Sleigh says, “The project is an excellent example of trans-Tasman co-operation in biotech, building on the complementary skills of our two companies to address what we hope to establish as an exciting new target for anti-inflammatory drugs.”

“Companies in the Australasian region need to work together to maximise the value of their intellectual property as they develop products for the global health market,” said Dr Douglas Williams, Head of Health for Genesis Research. “The combination of expertise and intellectual property in Genesis Research and EvoGenix makes us ideal partners in exploring this very interesting opportunity.”

ENDS About Genesis
Founded in 1994, Genesis is a New Zealand-based biotechnology company committed to the building of a broad genomic platform for the development of innovative products in health and plant biotechnology. Genesis partners with industry leaders to develop products which have global market potential through the mining of its extensive microbe, plant and mammalian EST databases.

The Health Division has three programmes in human clinical development for the treatment of psoriasis, atopic dermatitis (eczema) and asthma, with additional programmes for cancer and other indications in pre-clinical development. The patented BioStore solutions for storage of tissues and living cells are also in pre-clinical development. Collaborations are maintained with Amgen Inc. (NASDAQ: AMGN), Corixa Corporation (NASDAQ: CRXA), SR Pharma (LSE: SPA), and Jurox Pty Ltd.

The Plant division has research collaborations with ArborGen, Wrightson (NZSE: WRI), HortResearch, AgResearch, and Landcare. Genesis is also undertaking significant unpartnered research programmes in novel plant hormones.

The company has an extensive health and plant patent portfolio.


© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

I Sing The Highway Electric: Charge Net NZ To Connect New Zealand

BMW is turning Middle Earth electric after today announcing a substantial contribution to the charging network Charge Net NZ. This landmark partnership will enable Kiwis to drive their electric vehicles (EVs) right across New Zealand through the installation of a fast charging highway stretching from Kaitaia to Invercargill. More>>

ALSO:

Watch This Space: Mahia Rocket Lab Launch Site Officially Opened

Economic Development Minster Steven Joyce today opened New Zealand’s first orbital launch site, Rocket Lab Launch Complex 1, on the Mahia Peninsula on the North Island’s east coast. More>>

Earlier:

Marketing Rocks!
Ig Nobel Award Winners Assess The Personality Of Rocks

A Massey University marketing lecturer has received the 2016 Ig Nobel Prize for economics for a research project that asked university students to describe the “brand personalities” of three rocks. More>>

ALSO:

Nurofen Promotion: Reckitt Benckiser To Plead Guilty To Misleading Ads

Reckitt Benckiser (New Zealand) intends to plead guilty to charges of misleading consumers over the way it promoted a range of Nurofen products, the Commerce Commission says. More>>

ALSO:

Half A Billion Accounts, Including Xtra: Yahoo Confirms Huge Data Breach

The account information may have included names, email addresses, telephone numbers, dates of birth, hashed passwords (the vast majority with bcrypt) and, in some cases, encrypted or unencrypted security questions and answers. More>>

ALSO:

Rural Branches: Westpac To Close 19 Branches, ANZ Looks At 7

Westpac confirms it will close nineteen branches across the country; ANZ closes its Ngaruawahia branch and is consulting on plans to close six more branches; The bank workers union says many of its members are nervous about their futures and asking ... More>>

Interest Rates: RBNZ's Wheeler Keeps OCR At 2%

Reserve Bank governor Graeme Wheeler kept the official cash rate at 2 percent and said more easing will be needed to get inflation back within the target band. More>>

ALSO:

Get More From Scoop

 
 
 
 
 
 
 
 
 
Sci-Tech
Search Scoop  
 
 
Powered by Vodafone
NZ independent news